Technical Analysis for FOLD - Amicus Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical FOLD trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
20 DMA Resistance | Bearish | -6.25% | |
Up 3 Days in a Row | Strength | -6.25% | |
50 DMA Support | Bullish | -4.98% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.98% | |
NR7 | Range Contraction | -4.98% | |
NR7-2 | Range Contraction | -4.98% | |
NR7 | Range Contraction | -4.36% | |
20 DMA Resistance | Bearish | -3.77% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Trending on StockTwits | 2 days ago | |
Fell Below Lower Bollinger Band | 2 days ago | |
Lower Bollinger Band Support | 2 days ago | |
Down 5% | 2 days ago | |
Down 1 ATR | 2 days ago |
Get a Trading Assistant
- Earnings date: 03/01/2021
Amicus Therapeutics, Inc. Description
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Glaxosmithkline Orphan Disease Orphan Diseases Inborn Errors Of Metabolism Lipid Storage Disorders Enzyme Replacement Therapy Fabry Disease Gaucher Disease Lysosomal Storage Disorder Orphan Drugs Lysosomal Storage Disorders Pompe Disease Protein Folding Rare And Orphan Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 25.39 |
52 Week Low | 6.25 |
Average Volume | 2,304,699 |
200-Day Moving Average | 16.14 |
50-Day Moving Average | 22.73 |
20-Day Moving Average | 23.26 |
10-Day Moving Average | 22.80 |
Average True Range | 1.15 |
ADX | 18.87 |
+DI | 21.74 |
-DI | 23.05 |
Chandelier Exit (Long, 3 ATRs ) | 21.95 |
Chandelier Exit (Short, 3 ATRs ) | 24.79 |
Upper Bollinger Band | 24.90 |
Lower Bollinger Band | 21.61 |
Percent B (%b) | 0.07 |
BandWidth | 14.14 |
MACD Line | 0.03 |
MACD Signal Line | 0.20 |
MACD Histogram | -0.1709 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 24.18 | ||||
Resistance 3 (R3) | 24.43 | 23.90 | 23.79 | ||
Resistance 2 (R2) | 23.90 | 23.30 | 23.77 | 23.66 | |
Resistance 1 (R1) | 22.87 | 22.93 | 22.60 | 22.62 | 23.53 |
Pivot Point | 22.33 | 22.33 | 22.20 | 22.21 | 22.33 |
Support 1 (S1) | 21.30 | 21.73 | 21.03 | 21.05 | 20.14 |
Support 2 (S2) | 20.77 | 21.36 | 20.64 | 20.01 | |
Support 3 (S3) | 19.74 | 20.77 | 19.88 | ||
Support 4 (S4) | 19.49 |